Lineage library
Scientific lineages behind disease breakthroughs
Each history starts with a current clinical development and traces backward through the full scientific lineage that made it possible — the discoveries, tools, models, failures, and decisions across decades of research.
Published lineages
Daraxonrasib in pancreatic cancer
Phase 2KRAS-directed therapy traced through oncogene discovery, structural biology, medicinal chemistry, and translational oncology
Gene therapy for inherited retinal disease
Approved (Luxturna)Gene therapy for inherited blindness traced through retinal biology, disease genetics, AAV vector engineering, and surgical delivery
RNA-targeted therapy for Angelman syndrome
Phase 3How UBE3A biology and antisense oligonucleotides led to a Phase 3 rare-disease trial (REVEAL / NCT06914609)
Part of the broader RNA medicine for rare genetic disease platform lineage.
Lineages in development
These lineages are under active research and will be published as investigations are completed.
GLP-1 therapies and metabolic disease
Medical advance: GLP-1 medicines for diabetes and obesity
Lineage: Gut hormone biology, incretin signaling, peptide pharmacology, metabolic physiology
How basic hormone biology became large-scale metabolic medicine
Cancer immunotherapy / checkpoint inhibitors
Medical advance: Immune checkpoint blockade for cancer
Lineage: T-cell biology, immune tolerance, tumor immune evasion, monoclonal antibody engineering
How basic immunology changed cancer treatment
Platform lineages
Some scientific platforms span multiple trial-anchored lineages. These are tracked as broader platform lineages, with individual histories published separately.
RNA medicine for rare genetic disease
RNA-targeted therapies — including antisense oligonucleotides, siRNA, exon skipping, and splicing modulators — represent a platform with multiple trial-anchored lineages. The Angelman syndrome lineage above is the first published from this platform. Additional RNA medicine lineages may follow.
Platform lineage in developmentWant to suggest a disease area or scientific history for investigation?
TrialLineage welcomes suggestions from patients, researchers, and the public.
cases@triallineage.org